Advertisement

Cost-effectiveness of population-wide genomic screening for familial hypercholesterolemia in the United States

      Highlights

      • We modeled population genomic FH screening for cost-effectiveness.
      • Population FH genomic screening is not cost-effective at current willingness-to-pay.
      • Population genomic FH screening improves overall population health.
      • Lower genomic costs and/or multiplex screening are needed to be cost-effective.

      Background

      Population genomic screening for familial hypercholesterolemia (FH) in unselected individuals can prevent premature cardiovascular disease.

      Objective

      To estimate the clinical and economic outcomes of population-wide FH genomic screening versus no genomic screening.

      Methods

      We developed a decision tree plus 10-state Markov model evaluating the identification of patients with an FH variant, statin treatment status, LDL-C levels, MI, and stroke to compare the costs, quality-adjusted life-years (QALYs), and incremental cost-effectiveness of population-wide FH genomic screening. FH variant prevalence (0.4%) was estimated from the Geisinger MyCode Community Health Initiative (MyCode). Genomic test costs were assumed to be $200. Age and sex-based estimates of MI, recurrent MI, stroke, and recurrent stroke were obtained from Framingham risk equations. Additional outcomes independently associated with FH variants were derived from a retrospective analysis of 26,025 participants screened for FH. Sensitivity and threshold analyses were conducted to evaluate model assumptions and uncertainty.

      Results

      FH screening was most effective at younger ages; screening unselected 20-year-olds lead to 111 QALYs gained per 100,000 individuals screened at an incremental cost of $20 M. The incremental cost-effectiveness ratio (ICER) for 20-year-olds was $181,000 per QALY, and there was a 38% probability of cost-effectiveness at a $100,000 per QALY willingness-to-pay threshold. If genomic testing cost falls to $100, the ICER would be $91,000 per QALY.

      Conclusion

      Population FH screening is not cost-effective at current willingness to pay thresholds. However, reducing test costs, testing at younger ages, or including FH within broader multiplex screening panels may improve clinical and economic value.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Journal of Clinical Lipidology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Khera A.V.
        • Won H.-H.
        • Peloso G.M.
        • et al.
        Diagnostic yield and clinical utility of sequencing familial hypercholesterolemia genes in patients with severe hypercholesterolemia.
        J Am Coll Cardiol. 2016; 67: 2578-2589
        • Benn M.
        • Watts G.F.
        • Tybjærg-Hansen A.
        • Nordestgaard B.G.
        Mutations causative of familial hypercholesterolaemia: screening of 98 098 individuals from the Copenhagen General Population Study estimated a prevalence of 1 in 217.
        Eur Heart J. 2016; 37: 1384-1394
        • Sjouke B.
        • Kusters D.M.
        • Kindt I.
        • et al.
        Homozygous autosomal dominant hypercholesterolaemia in the Netherlands: prevalence, genotype–phenotype relationship, and clinical outcome.
        Eur Heart J. 2015; 36: 560-565
        • Henderson R.
        • O'Kane M.
        • McGilligan V.
        • Watterson S.
        The genetics and screening of familial hypercholesterolaemia.
        J Biomed Sci. 2016; 23: 1-12
        • Sturm A.C.
        • Knowles J.W.
        • Gidding S.S.
        • et al.
        Clinical genetic testing for familial hypercholesterolemia: JACC scientific expert panel.
        J Am Coll Cardiol. 2018; 72: 662-680
        • Goldberg A.C.
        • Hopkins P.N.
        • Toth P.P.
        • et al.
        Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients: clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia.
        J Clin Lipidol. 2011; 5: 133-140
        • Trinder M.
        • Francis G.A.
        • Brunham L.R.
        Association of monogenic vs polygenic hypercholesterolemia with risk of atherosclerotic cardiovascular disease.
        JAMA Cardiol. 2020; 5: 390-399
        • Lamiquiz-Moneo I.
        • Civeira F.
        • Mateo-Gallego R.
        • et al.
        Diagnostic yield of sequencing familial hypercholesterolemia genes in individuals with primary hypercholesterolemia.
        Revista Española de Cardiología (English Edition). 2021; 74: 664-673
      1. Familial hypercholesterolemia - Genetics Home Reference - NIH. (n.d.). Retrieved from https://ghr.nlm.nih.gov/condition/familial-hypercholesterolemia

        • Nordestgaard B.G.
        • Chapman M.J.
        • Humphries S.E.
        • et al.
        Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society.
        Eur Heart J. 2013; 34: 3478-3490
        • Neil H.
        • Hammond T.
        • Huxley R.
        • Matthews D.
        • Humphries S.
        Extent of underdiagnosis of familial hypercholesterolaemia in routine practice: prospective registry study.
        BMJ. 2000; 321: 148
        • Pijlman A.H.
        • Huijgen R.
        • Verhagen S.
        • et al.
        Evaluation of cholesterol lowering treatment of patients with familial hypercholesterolemia: a large cross-sectional study in The Netherlands.
        Atherosclerosis. 2010; 209: 189-194
        • Abul-Husn N.S.
        • Manickam K.
        • Jones L.K.
        • et al.
        Genetic identification of familial hypercholesterolemia within a single US health care system.
        Science. 2016; 354
        • Centers for Disease Control and Prevention
        Tier 1 Genomics Applications and their Importance to Public Health. 2014; (PublishedAccessed 8/1/2021)
        • Degoma E.M.
        • Ahmad Z.S.
        • O'Brien E.C.
        • et al.
        Treatment gaps in adults with heterozygous familial hypercholesterolemia in the United States: data from the CASCADE-FH registry.
        Circulation. 2016; 9: 240-249
        • Wilemon K.A.
        • Patel J.
        • Aguilar-Salinas C.
        • et al.
        Reducing the clinical and public health burden of familial hypercholesterolemia: a global call to action.
        JAMA Cardiol. 2020; 5: 217-229
        • Nherera L.
        • Marks D.
        • Minhas R.
        • Thorogood M.
        • Humphries S.
        Probabilistic cost-effectiveness analysis of cascade screening for familial hypercholesterolaemia using alternative diagnostic and identification strategies.
        Heart. 2011; 97: 1175-1181
        • Ademi Z.
        • Watts G.F.
        • Pang J.
        • et al.
        Cascade screening based on genetic testing is cost-effective: evidence for the implementation of models of care for familial hypercholesterolemia.
        J Clin Lipidol. 2014; 8: 390-400
        • Chen C.X.
        • Hay J.W.
        Cost-effectiveness analysis of alternative screening and treatment strategies for heterozygous familial hypercholesterolemia in the United States.
        Int J Cardiol. 2015; 181: 417-424
        • Pelczarska A.
        • Jakubczyk M.
        • Jakubiak-Lasocka J.
        • et al.
        The cost-effectiveness of screening strategies for familial hypercholesterolaemia in Poland.
        Atherosclerosis. 2018; 270: 132-138
        • Civeira F.
        Hypercholesterolemia IPoMoF. Guidelines for the diagnosis and management of heterozygous familial hypercholesterolemia.
        Atherosclerosis. 2004; 173: 55-68
        • Neumann P.J.
        • Sanders G.D.
        • Russell L.B.
        • Siegel J.E.
        • Ganiats T.G.
        Cost-effectiveness in health and medicine.
        Oxford University Press, 2016
        • D'Agostino Sr, R.B.
        • Vasan R.S.
        • Pencina M.J.
        • et al.
        General cardiovascular risk profile for use in primary care: the Framingham Heart Study.
        Circulation. 2008; 117: 743-753
        • Virani S.S.
        • Alonso A.
        • Benjamin E.J.
        • et al.
        Heart disease and stroke statistics—2020 update: a report from the American Heart Association.
        Circulation. 2020; 141: e139-e596
        • Jernberg T.
        • Hasvold P.
        • Henriksson M.
        • Hjelm H.
        • Thuresson M.
        • Janzon M.
        Cardiovascular risk in post-myocardial infarction patients: nationwide real world data demonstrate the importance of a long-term perspective.
        Eur Heart J. 2015; 36: 1163-1170
        • Luirink I.K.
        • Wiegman A.
        • Kusters D.M.
        • et al.
        20-year follow-up of statins in children with familial hypercholesterolemia.
        N Engl J Med. 2019;
      2. Bogsrud M.P., Græsdal A., Johansen D., et al. LDL-cholesterol goal achievement, cardiovascular disease, and attributed risk of Lpain a large cohort of predominantly genetically verified familial hypercholesterolemia. J Clin Lipidol2019;13(2):279-286.

        • Virani S.S.
        • Alonso A.
        • Aparicio H.J.
        • et al.
        Heart disease and stroke statistics—2021 update: a report from the American Heart Association.
        Circulation. 2021; 143: e254-e743
        • Galper B.Z.
        • Wang Y.C.
        • Einstein A.J.
        Strategies for primary prevention of coronary heart disease based on risk stratification by the ACC/AHA Lipid Guidelines, ATP III Guidelines, Coronary Calcium Scoring, and C-Reactive Protein, and a Global Treat-All Strategy: a comparative–effectiveness modeling study.
        PLoS One. 2015; 10e0138092
        • Gandra S.R.
        • Villa G.
        • Fonarow G.C.
        • et al.
        Cost-effectiveness of LDL-C lowering with evolocumab in patients with high cardiovascular risk in the United States.
        Clin Cardiol. 2016; 39: 313-320
        • Lin L.
        • Teng M.
        • Zhao Y.J.
        • et al.
        Long-term cost-effectiveness of statin treatment for primary prevention of cardiovascular disease in the elderly.
        Cardiovasc Drugs Ther. 2015; 29: 187-197
      3. CPI inflation calculator. U.S. Bureau of Labor Statistics. https://www.bls.gov/data/inflation_calculator.htm.

      4. Color Genomics Inc. https://home.color.com/purchase/ordering-physician?sku=combo%203. Accessed 8/1/2021.

        • Pandya A.
        • Sy S.
        • Cho S.
        • Weinstein M.C.
        • Gaziano T.A.
        Cost-effectiveness of 10-year risk thresholds for initiation of statin therapy for primary prevention of cardiovascular disease.
        JAMA. 2015; 314: 142-150
        • O'Sullivan A.K.
        • Rubin J.
        • Nyambose J.
        • Kuznik A.
        • Cohen D.J.
        • Thompson D.
        Cost estimation of cardiovascular disease events in the US.
        Pharmacoeconomics. 2011; 29: 693-704
      5. Quick Facts - United States. United States Census Bureau. (n.d.). https://www.census.gov/quickfacts/fact/table/US/LFE046219.

        • Attipoe-Dorcoo S.
        • Yang P.
        • Sperling L.
        • et al.
        Characteristics and trends of PCSK9 inhibitor prescription fills in the United States.
        J Clin Lipidol. 2021; 15: 332-338
      6. Center for Drug Evaluation and Research. FDA approves drug for rare forms of high cholesterol. U.S. Food and Drug Administration. https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-add-drug-ages-10-rare-forms-high-cholesterol.

        • Jackson C.L.
        • Deng Y.
        • Yao X.
        • Van Houten H.
        • Shah N.D.
        • Kopecky S.
        Proprotein convertase subtilisin/kexin type 9 inhibitor utilization and low-density lipoprotein-cholesterol control in familial hypercholesterolemia.
        J Clin Lipidol. 2021; 15: 339-346
        • Sabatine M.S.
        PCSK9 inhibitors: clinical evidence and implementation.
        Nat Rev Cardiol. 2019; 16: 155-165
        • Chamberlain A.M.
        • Gong Y.
        • Shaw K.M.
        • et al.
        PCSK9 inhibitor use in the real world: data from the National Patient-Centered Research Network.
        J Am Heart Assoc. 2019; 8e011246
        • Patel J.
        Managed care pharmacist updates for proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors.
        Am J Manag Care. 2021; 27 (Suppl): S76-S82
      7. AHA. (n.d.). Cardiovascular disease: A costly burden for America projections through 2035. American Heart Association CVD Burden Report. Retrieved from https://www.heart.org/idc/groups/heart-public/@wcm/@adv/documents/downloadable/ucm_491543.pdf.

        • Ademi Z.
        • Marquina C.
        • Lacaze P.
        • et al.
        Population genomic screening of all young adults in Australia to detect familial hypercholesterolemia: a cost-effectiveness analysis.
        Eur Heart J. 2021; 42 (2727): ehab724
        • Guzauskas G.F.
        • Garbett S.
        • Zhou Z.
        • et al.
        Cost-effectiveness of Population-Wide Genomic Screening for Hereditary Breast and Ovarian Cancer in the United States.
        JAMA Netw Open. 2020; 3 (-e2022874)e2022874